Patogeneza i niektóre molekularne wskaźniki prognostyczne w raku żołądka
stric carcinomas. Aliment Pharmacol Ther 2002; 16(2): 128-36. 110. Fleisher AS, Esteller M, Tamura G et al.: Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001; 20(3): 32935. 111. Knudson AG: Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001; 1(2): 157-62. 112. Korf B: Genetyka człowieka. PWN 2004; 1-366. 113. Hsieh L, Huang Y: Loss of heterozygosity of APC/MCC gene in differentiated and undifferentiated gastric carcinomas in Taiwan. Cancer Lett 1995; 96(2): 169-74. 114. Matozaki T, Sakamoto C, Matsuda K et al.: Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem Biophys Res Commun 1992; 182(1): 215-23. 115. Iwamatsu H, Nishikura K, Watanabe H et al.: Heterogenity of p53 nutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer 2001; 4(1): 21-26. 116. El-Rifai W, Powell SM: Molecular Biology of Gastric Cancer. Sem Rad Onc 2002; 12(2): 128-40. 117. Tong JHM, To KF, Lay J et al.: Somatic Betacatenin mutation in gastric carcinoma – an infrequent event that is not specific for microsatellite instability. Cancer Lett 2001; 163(1): 125-30. 118. Tamura G, Sato K, Akiyama S et al.: Molecular Characterization of Undifferenciated – Type Gastric Carcinoma. Lab Invest 2001; 81(4): 593-98. 119. Kraus C, Liehr T, Hulsken J et al.: Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics 1994; 23(1): 272-74. 120. Morin PJ, Sparks AB, Korinek V et al.: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275(5307): 1787-90. 121. Korinek V, Barker N, Morin PJ et al.: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275(5307): 1784-87. 122. Utsunomiya T, Doki Y, Takemoto H et al.: Clinical significance of disordered beta-catenin expression pattern in human gastric cancers. Gastric Cancer 2000; 3(4): 193-201. 123. Shimoyama Y, Hirohashi S: Expression of Eand P-cadherin in gastric carcinomas. Cancer Res 1991; 51(8): 2185-92. 124. Stone J, Bevan S, Cunningham D et al.: Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer 1999; 79(11-12): 1935-37. 125. Guilford P: E-cadherin downregulation in cancer: fuel on the fire? Mol Med Today 1999; 5(4):17277. 126. Wijnhoven BP, Dinjens WN, Pignatelli M: Ecadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg 2000; 87(8): 992-1005. 127. Berx G, Staes K, van Hengel J et al.: Cloning and characterization of the human invasion suppres-
503
sor gene E-cadherin (CDH1). Genomics 1995; 26(2): 281-89. 128. Becker KF, Atkinson MJ, Reich U et al.: E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54(14): 3845-52. 129. Graff JR, Herman JG, Lapidus RG et al.: Ecadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55(22): 5195-99. 130. Tamura G, Sato K, Akiyama S et al.: Molecular Characterization of Undifferenciated-Type Gastric Carcinoma. Lab Invest 2001; 81(4): 593-98. 131. Perl AK, Wilgenbus P, Dahl U et al.: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392(6672): 190-93. 132. Mansouri A, Goodfellow PN, Kemler R: Molecular cloning and chromosomal localization of the human cell adhesion molecule uvomorulin (UVO). Cytogenet Cell Genet 1987; 46(1): 655. 133. Becker KF, Reich U, Schott C et al.: Single nucleotide polymorphisms in the human E-cadherin gene. Hum Genet 1995; 96(6): 739-40. 134. Pecina-Slaus N: Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 2003; 3(1): 1-7. 135. Zazula M, Ferreira AM, Czopek JP et al.: CDH1 gene promoter hypermethylation in gastric cancer: relationship to Goseki grading, microsatellite instability status and EBV invasion. Diagn Mol Pathol. 2006; 15(1): 24-29. 136. Berx G, Becker K, Hoefler H et al.: Mutations of the CDH1 Gene. Hum Mutat 1998; 12(5): 226-37. 137. Latham KE: X chromosome imprinting and inactivation in the early mammalian embryo. Trends Genet 1996; 12(4): 134-38. 138. Issa JP, Ottaviano YL, Celano P et al.: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7(4): 536-40. 139. Nguyen C, Liang G, Nguyen TT et al.: Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001; 93(19): 1465-72. 140. Esteller M, Corn PG, Baylin SB et al.: A gene hypermethylation profile of human cancer. Cancer Res 2001; 61(8): 3225-29. 141. Grady WM, Willis J, Guilford PJ et al.: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genet 2000; 26: 16-17. 142. Graziano F, Arduini F, Ruzzo A et al.: Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, nodepositive, diffuse gastric cancer. Clin Cancer Res 2004; 10(8): 2784-89. 143. Rountree MR, Bachman KE, Herman JG et al.: DNA methylation, chromatin inheritance, and cancer. Oncogene 2001; 20(24): 3156-65. 144. Arber N, Shapira I, Ratan J et al.: Activation of c-K-ras mutations in Human Gastrointestinal Tumors. Gastroenterology 2000; 118(6): 1045-50.